DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR CLARINEX D 24 HOUR

« Back to Dashboard

All Clinical Trials for Clarinex D 24 Hour

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00636870	Fexofenadine (Allegra®) in Healthy Adults Who Have Been Identified as Slow Metabolizers for Desloratadine	Completed	Sanofi	Phase 4	2003-02-01	To evaluate the single-dose and steady-state pharmacokinetics of desloratadine and fexofenadine in desloratadine slow metabolizers. To evaluate the safety and tolerability of desloratadine compared to fexofenadine following single and multiple oral doses administered to desloratadine slow metabolizers.
NCT00637585	Fexofenadine HCl 180 mg, Desloratadine 5 mg and Placebo in Suppression of Wheal and Flare Induced by Histamine	Completed	Sanofi	Phase 4	2002-12-01	To examine the relative potency, onset of action and duration of action of fexofenadine HCl 180 mg (ALLEGRA) and desloratadine 5 mg (CLARINEX) as compared to placebo on skin wheals and flares induced by histamine.
NCT00783133	Preference for Clarinex Tablets vs. Allegra Tablets in Patients With Seasonal Allergies (Study P03177)	Completed	Merck Sharp & Dohme Corp.	Phase 4	2002-11-01	This was a crossover study designed to see if patients with seasonal allergy symptoms preferred Clarinex® or Allegra®. Patients were randomized to take 7 days of Clarinex or Allegra treatment, followed by a 5 to 28-day washout period (days when no drug is given), followed by 7 days of the opposite treatment. At the end of each 7-day treatment, patients were asked questions to determine which drug, Clarinex or Allegra, the patient prefers more.
NCT00794248	Preference for Clarinex Tablets vs. Allegra Tablets in Patients With Seasonal Allergies (Study P03179)	Completed	Merck Sharp & Dohme Corp.	Phase 4	2002-11-01	This was a crossover study designed to see if patients with seasonal allergy symptoms preferred Clarinex® or Allegra®. Patients were randomized to take 7 days of Clarinex or Allegra treatment, followed by a 5 to 28-day washout period (days when no drug is given), followed by 7 days of the opposite treatment. At the end of each 7-day treatment, patients were asked questions to determine which drug, Clarinex or Allegra, the patient prefers more.

Clinical Trial Conditions for Clarinex D 24 Hour

Condition Name

Condition Name for Clarinex D 24 Hour
Intervention	Trials
Seasonal Allergic Rhinitis	7
Healthy	4
Perennial Allergic Rhinitis	3
Allergic Rhinitis	2

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Clarinex D 24 Hour
Intervention	Trials
Rhinitis, Allergic	9
Rhinitis	9
Rhinitis, Allergic, Seasonal	7
Rhinitis, Allergic, Perennial	3

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Clarinex D 24 Hour

Trials by Country

Trials by Country for Clarinex D 24 Hour
Location	Trials
United States	8
Canada	1

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Clarinex D 24 Hour
Location	Trials
Florida	5
New Jersey	2
Kentucky	1

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Clarinex D 24 Hour

Clinical Trial Phase

Clinical Trial Phase for Clarinex D 24 Hour
Clinical Trial Phase	Trials
Phase 4	9
Phase 3	1
Phase 2	1

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Clarinex D 24 Hour
Clinical Trial Phase	Trials
Completed	17

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Clarinex D 24 Hour

Sponsor Name

Sponsor Name for Clarinex D 24 Hour
Sponsor	Trials
Merck Sharp & Dohme Corp.	8
Dr. Reddy's Laboratories Limited	6
Sanofi	2

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Clarinex D 24 Hour
Sponsor	Trials
Industry	17
Other	1

Export unavailable in trial.
Subscribe for complete access.